FDA fields queries from consumers, reports update from manufacturer.
The U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine reports that it has recently received a number of phone calls and e-mails from consumers who’ve been unable to obtain Adequan IM and IA (polysulfated glycosaminoglycan) and Adequan Canine. Adequan is an FDA-approved drug for the control of signs associated with non-infectious degenerative and traumatic lameness in horses and dogs.
In response to these inquiries, the FDA says it contacted Luitpold Pharmaceuticals, the manufacturer of Adequan, and learned that the product will be available again beginning later in August. As reported earlier by dvm360.com (see the articles “Adequan shortage imminent due to FDA-driven factory renovations” and “Adequan Canine ‘extremely limited’ due to plant renovations”), production of Adequan was halted due to renovations and improvements at its Shirley, N.Y., manufacturing plant to address issues cited by the FDA. Now, those issues appear close to being resolved.
“Luitpold has been working closely with the Food and Drug Administration to assure that Adequan is made available as soon as possible,” a release from the company states.
For more information and updates on product availability, visit www.adequan.com or call Luitpold Animal Health Customer Service at (800) 458-0163.